Innovative Dual-Action Bacterial Cancer Therapy Developed by Jeonbuk National University Researchers

Innovative Bacterial Cancer Therapy



Jeonbuk National University has taken a significant step in cancer treatment by developing a dual-action therapy utilizing engineered bacteria. Traditional cancer therapies often encounter resistance, recurrence, and metastasis, making it challenging to manage tumors effectively. In a groundbreaking effort led by Professor John Hwa Lee and his team from the Laboratory of Veterinary Public Health, the researchers engineered a strain of Salmonella Typhimurium, which is known to naturally accumulate in tumors, to carry two anticancer components.

The Dual-Action Approach


The engineered bacteria, named JOL3136, has been designed to express two critical elements: apoptin, which induces cell death in cancer cells, and carcinoembryonic antigen (CEA) epitopes that activate the immune response against tumors. To enhance the bacterium's targeting capabilities, specific genes—trpA, trpE, asd, and pagL—were deleted, making the bacteria dependent on tryptophan. The JOL3136 strain was then carefully passaged in tumor-bearing mice to improve localization within the tumors.

When tested on 4T1 cells, a highly metastatic mouse breast cancer cell line, the results were remarkable. The JOL3136-treated cells exhibited greater rates of both early and late apoptosis compared to untreated controls. Furthermore, in vivo studies demonstrated a significant reduction in tumor mass and volume; the reduction in the JOL3136-treated mice surpassed that seen in the vector-control group by more than 200%.

Immune Response Enhancement


In addition to its direct effects on cancer cells, the therapy also modified the immune landscape within tumors. JOL3136 treatment led to an increase in CD49b-positive lymphocytes and levels of interferon-gamma (IFN-γ), indicating a robust immune activity that could suppress cancer spread. Subsequent experiments revealed a marked decrease in labeled cancer cells in the lungs, liver, and spleen of JOL3136-treated mice compared to controls, suggesting a dual mechanism of action: direct tumor destruction and immune activation.

Professor Lee highlighted the significant implications of this dual-action therapy, stating, "Cancer treatment needs ways to reach tumors while also addressing the immune environment that can help them persist." He emphasized the potential of combining a bacterial delivery system with agents that promote cancer cell death and antitumor immunity.

Future Considerations


While these findings offer a promising proof-of-concept for treating aggressive breast cancer, the journey to clinical application is still fraught with challenges. The researchers noted that modifications to the bacterial carrier could allow them to deliver other therapeutic agents in the future. However, crucial steps including the establishment of stringent safety measures and evaluations in more representative models of human disease are necessary before considering this therapy for clinical use.

Live Salmonella therapies come with inherent risks of infection, necessitating thorough testing to determine safe and effective use. As the research progresses, it will be vital to assess the contributions of each component of the therapy and ensure biosafety measures are robust enough to mitigate risks.

Conclusion


The innovative work at Jeonbuk National University represents a significant advancement in the fight against cancer, particularly in challenging cases of breast cancer. By leveraging the unique properties of engineered bacteria, the researchers have opened new pathways for targeted treatment strategies that encompass both direct tumor destruction and the activation of the immune system. Moving forward, the scientific community eagerly anticipates further studies that will translate these promising preclinical results into viable clinical therapies.

For further reading, refer to the original paper titled "Therapeutic Salmonella expressing apoptin and CEA elicits combined pro-apoptotic and immune-mediated anticancer effects," published in the journal Biomedicine & Pharmacotherapy.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.